Literature DB >> 8384570

Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studies.

N Suman-Chauhan1, L Webdale, D R Hill, G N Woodruff.   

Abstract

The binding characteristics of [3H]gabapentin, the radiolabelled analogue of the novel anticonvulsant gabapentin (1-(aminomethyl)cyclohexaneacetic acid) were studied using purified synaptic plasma membranes prepared from rat cerebral cortex. In 10 mM HEPES buffer [3H]gabapentin bound to a single population of sites with high affinity (KD = 38 +/- 2.8 nM) with a maximum binding capacity of 4.6 +/- 0.4 pmol/mg protein, reaching equilibrium after 30 min at 20 degrees C. This novel site was unique to the central nervous system with little or no specific [3H]gabapentin being measurable in a range of peripheral tissues. Binding was potently inhibited by a range of gabapentin analogues and 3-alkyl substituted gamma-aminobutyric acid (GABA) derivates although GABA itself and the selective GABAB receptor ligand baclofen, were only weakly active. Gabapentin itself (IC50 = 80 nM) and 3-isobutyl GABA (IC50 = 80 nM) which also has anticonvulsant properties, showed the highest affinity for the binding site. Of a wide range of other pharmacologically active compounds only the polyamines spermine and spermidine influenced [3H]gabapentin binding, with both compounds producing a maximum of 50% inhibition of specific binding. Magnesium ions produced a similar pattern of inhibition but the effect of the polyamines and magnesium ions were not additive. The data provide evidence for the existence in brain of a novel binding site that may mediate the anticonvulsant effects of gabapentin and other potential anticonvulsant compounds.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384570     DOI: 10.1016/0922-4106(93)90155-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  34 in total

Review 1.  P/Q-type calcium channel modulators.

Authors:  V Nimmrich; G Gross
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

Review 2.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  New Horizons in the development of antiepileptic drugs: Innovative strategies.

Authors:  Wolfgang Löscher; Dieter Schmidt
Journal:  Epilepsy Res       Date:  2006-06       Impact factor: 3.045

Review 4.  Pregabalin in the treatment of chronic pain: an overview.

Authors:  S Chiechio; M Zammataro; F Caraci; L Rampello; A Copani; A F Sabato; F Nicoletti
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

5.  Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis.

Authors:  Cagla Eroglu; Nicola J Allen; Michael W Susman; Nancy A O'Rourke; Chan Young Park; Engin Ozkan; Chandrani Chakraborty; Sara B Mulinyawe; Douglas S Annis; Andrew D Huberman; Eric M Green; Jack Lawler; Ricardo Dolmetsch; K Christopher Garcia; Stephen J Smith; Z David Luo; Arnon Rosenthal; Deane F Mosher; Ben A Barres
Journal:  Cell       Date:  2009-10-08       Impact factor: 41.582

6.  Involvement of NO/cGMP pathway in the antidepressant-like effect of gabapentin in mouse forced swimming test.

Authors:  Sattar Ostadhadi; Nastaran Kordjazy; Arya Haj-Mirzaian; Sanaz Ameli; Golnoosh Akhlaghipour; AhmadReza Dehpour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-01-12       Impact factor: 3.000

7.  Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats.

Authors:  Z D Luo; S R Chaplan; E S Higuera; L S Sorkin; K A Stauderman; M E Williams; T L Yaksh
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

8.  Modulation of voltage-gated Ca2+ channels in rat retinal ganglion cells by gabapentin.

Authors:  Spring R Farrell; Allison Sargoy; Nicholas C Brecha; Steven Barnes
Journal:  Vis Neurosci       Date:  2014-01       Impact factor: 3.241

9.  Gabapentin enacarbil - clinical efficacy in restless legs syndrome.

Authors:  Pinky Agarwal; Alida Griffith; Henry R Costantino; Narendra Vaish
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

10.  Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?

Authors:  Emin Onder; Umit Tural; Mehmet Gökbakan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-02-23       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.